Clinical Trial Update: Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis [Phase 3]

View source ↗

Summary

Open-label extension study evaluating secukinumab for active lupus nephritis was terminated; results were posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Lupus Nephritis | Phase 3 | Status: TERMINATED | Results posted: 2024-08-30